• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

接受睾丸切除术和雌激素治疗的前列腺癌患者的骨矿物质密度

Bone mineral density in patients with prostatic cancer treated with orchidectomy and with estrogens.

作者信息

Eriksson S, Eriksson A, Stege R, Carlström K

机构信息

Department of Orthopedics, Karolinska Institutet, Huddinge University Hospital, Sweden.

出版信息

Calcif Tissue Int. 1995 Aug;57(2):97-9. doi: 10.1007/BF00298427.

DOI:10.1007/BF00298427
PMID:7584882
Abstract

Bone mineral density (BMD) and bone mineral content (BMC) were measured in the femoral neck area, trochanteric area and Wards triangle, and in the distal radius of the left forearm before and after 1 year of endocrine treatment in 27 patients with prostatic cancer. Eleven of the patients were treated with orchidectomy and 16 with combined oral and intramuscular estrogens. The patients were free from metastases during the entire observation period. In the orchidectomized patients, BMD and BMC of the distal radius decreased significantly following treatment, whereas no changes were observed in the estrogen-treated patients. These preliminary results demonstrate that estrogens may protect bone in male subjects also and may merit further investigations on larger groups of patients.

摘要

对27例前列腺癌患者在进行1年内分泌治疗前后,测量其股骨颈区域、转子区和沃德三角区以及左前臂桡骨远端的骨密度(BMD)和骨矿物质含量(BMC)。其中11例患者接受了睾丸切除术,16例接受了口服和肌肉注射雌激素联合治疗。在整个观察期内,患者均无转移。在接受睾丸切除术的患者中,治疗后桡骨远端的BMD和BMC显著下降,而接受雌激素治疗的患者未观察到变化。这些初步结果表明,雌激素也可能对男性骨骼有保护作用,值得对更多患者群体进行进一步研究。

相似文献

1
Bone mineral density in patients with prostatic cancer treated with orchidectomy and with estrogens.接受睾丸切除术和雌激素治疗的前列腺癌患者的骨矿物质密度
Calcif Tissue Int. 1995 Aug;57(2):97-9. doi: 10.1007/BF00298427.
2
Adrenocortical function in prostatic cancer patients: effects of orchidectomy or different modes of estrogen treatment on basal steroid levels and on the response to exogenous adrenocorticotropic hormone.前列腺癌患者的肾上腺皮质功能:睾丸切除术或不同方式雌激素治疗对基础类固醇水平及对外源性促肾上腺皮质激素反应的影响。
Urol Int. 1990;45(3):160-3. doi: 10.1159/000281699.
3
Possible bone-preserving capacity of high-dose intramuscular depot estrogen as compared to orchidectomy in the treatment of patients with prostatic carcinoma.与睾丸切除术相比,大剂量肌肉注射长效雌激素在治疗前列腺癌患者时可能具有的保骨能力。
Prostate. 1997 May 15;31(3):193-7. doi: 10.1002/(sici)1097-0045(19970515)31:3<193::aid-pros8>3.0.co;2-m.
4
Comparison of endocrine and radiation therapy in locally advanced prostatic cancer.局部晚期前列腺癌内分泌治疗与放射治疗的比较
Eur Urol. 1988;15(3-4):182-6. doi: 10.1159/000473429.
5
Orchiectomy, estrogen therapy and radiotherapy in locally advanced (T3-4 M0) prostatic cancer.局部晚期(T3-4 M0)前列腺癌的睾丸切除术、雌激素治疗和放射治疗。
Scand J Urol Nephrol Suppl. 1988;110:103-7.
6
Urethral obstruction secondary to carcinoma of prostate: response to endocrine treatment.
Urology. 1985 Apr;25(4):354-6. doi: 10.1016/0090-4295(85)90485-6.
7
Effects of orchidectomy and different modes of high dose estrogen treatment on circulating "free" and total 1,25-dihydroxyvitamin D in patients with prostatic cancer.睾丸切除术及不同方式大剂量雌激素治疗对前列腺癌患者循环中“游离”及总1,25 - 二羟维生素D的影响。
J Steroid Biochem Mol Biol. 1991 Aug;39(2):155-9. doi: 10.1016/0960-0760(91)90056-b.
8
Cardiovascular and all-cause mortality in prostatic cancer patients treated with estrogens or orchiectomy as compared to the standard population.与标准人群相比,接受雌激素或睾丸切除术治疗的前列腺癌患者的心血管死亡率和全因死亡率。
Prostate. 1991;18(2):131-7. doi: 10.1002/pros.2990180205.
9
Comparison of primary orchiectomy with oestrogen therapy in advanced prostatic cancer. A 2-year follow-up report of a national, prospective prostatic cancer study.
Br J Urol. 1986 Oct;58(5):528-33. doi: 10.1111/j.1464-410x.1986.tb05461.x.
10
Pretreatment hormone levels in prostatic cancer.前列腺癌的预处理激素水平。
Scand J Urol Nephrol Suppl. 1988;110:137-43.

引用本文的文献

1
2025 Canadian Urological Association-Canadian Uro-oncology Group Guideline: Metastatic castration-naive and castration-sensitive prostate cancer (Update).2025年加拿大泌尿外科学会-加拿大泌尿肿瘤学组指南:转移性去势初治和去势敏感性前列腺癌(更新版)
Can Urol Assoc J. 2025 May;19(5):E142-E152. doi: 10.5489/cuaj.9240.
2
The effect of caponization on bone homeostasis of crossbred roosters. I. Analysis of tibia bone mineralization, densitometric, osteometric, geometric and biomechanical properties.去势对杂交公鸡骨内稳态的影响。I. 分析胫骨骨矿化、密度计量学、骨计量学、几何和生物力学特性。
Sci Rep. 2023 Sep 4;13(1):14512. doi: 10.1038/s41598-023-41806-x.
3

本文引用的文献

1
Decreased bone density in elderly men treated with the gonadotropin-releasing hormone agonist decapeptyl (D-Trp6-GnRH).使用促性腺激素释放激素激动剂曲普瑞林(D-色氨酸6-促性腺激素释放激素)治疗的老年男性骨密度降低。
J Clin Endocrinol Metab. 1993 Feb;76(2):288-90. doi: 10.1210/jcem.76.2.7679397.
2
Steroid hormones, ageing and bone.
Clin Endocrinol Metab. 1981 Mar;10(1):115-39. doi: 10.1016/s0300-595x(81)80041-2.
3
Adrenocortical steroids, bone mineral content and endometrial condition in post-menopausal women.绝经后女性的肾上腺皮质类固醇、骨矿物质含量及子宫内膜状况
2022 UPDATE: Canadian Urological Association-Canadian Urologic Oncology Group guideline: Metastatic castration-naive and castration-sensitive prostate cancer Full-text.
2022年更新:加拿大泌尿外科学会-加拿大泌尿肿瘤学组指南:转移性去势初治和去势敏感性前列腺癌全文
Can Urol Assoc J. 2022 Dec;16(12):E581-E589. doi: 10.5489/cuaj.8148.
4
Canadian Urological Association-Canadian Urologic Oncology Group guideline on metastatic castration-naive and castration-sensitive prostate cancer.加拿大泌尿外科学会 - 加拿大泌尿肿瘤学组关于转移性去势初治和去势敏感性前列腺癌的指南
Can Urol Assoc J. 2020 Feb;14(2):17-23. doi: 10.5489/cuaj.6384. Epub 2019 Dec 5.
5
Effect of Androgen-Deprivation Therapy on Bone Mineral Density in Patients with Prostate Cancer: A Systematic Review and Meta-Analysis.雄激素剥夺疗法对前列腺癌患者骨密度的影响:一项系统评价和荟萃分析。
J Clin Med. 2019 Jan 18;8(1):113. doi: 10.3390/jcm8010113.
6
Estrogen therapy in patients with prostate cancer: a contemporary systematic review.前列腺癌患者的雌激素治疗:一项当代系统评价
Int Urol Nephrol. 2018 Jun;50(6):993-1003. doi: 10.1007/s11255-018-1854-5. Epub 2018 Mar 29.
7
Comparison of bone mineral loss by combined androgen block agonist versus GnRH in patients with prostate cancer: A 12 month-prospective observational study.比较联合雄激素阻断激动剂与 GnRH 在前列腺癌患者中引起的骨矿物质丢失:一项为期 12 个月的前瞻性观察研究。
Sci Rep. 2017 Mar 6;7:39562. doi: 10.1038/srep39562.
8
Sex differences in the estrogen-dependent regulation of temporomandibular joint remodeling in altered loading.负荷改变时雌激素依赖性颞下颌关节重塑调节中的性别差异。
Osteoarthritis Cartilage. 2017 Apr;25(4):533-543. doi: 10.1016/j.joca.2016.11.008. Epub 2016 Nov 27.
9
n-3 Polyunsaturated Fatty Acids and their Role in Cancer Chemoprevention.n-3多不饱和脂肪酸及其在癌症化学预防中的作用。
Curr Pharmacol Rep. 2015 Oct;1(5):283-294. doi: 10.1007/s40495-015-0043-9. Epub 2015 Jul 5.
10
Preservation of volumetric bone density and geometry in trans women during cross-sex hormonal therapy: a prospective observational study.跨性别女性接受跨性别激素治疗期间骨体积密度和骨几何形态的保留:一项前瞻性观察研究。
Osteoporos Int. 2015 Jan;26(1):35-47. doi: 10.1007/s00198-014-2805-3. Epub 2014 Nov 7.
Maturitas. 1982 Aug;4(2):113-22. doi: 10.1016/0378-5122(82)90037-8.
4
Treatment of prostate cancer with gonadotropin-releasing hormone agonists.
Endocr Rev. 1986 Feb;7(1):67-74. doi: 10.1210/edrv-7-1-67.
5
Bone mass in women with hip fracture.髋部骨折女性的骨量
Acta Orthop Scand. 1988 Feb;59(1):19-23. doi: 10.3109/17453678809149337.
6
Single drug polyestradiol phosphate therapy in prostatic cancer.单药聚磷酸雌二醇治疗前列腺癌
Am J Clin Oncol. 1988;11 Suppl 2:S101-3.
7
Prognostic value of serum hormone concentrations in prostatic cancer.血清激素浓度在前列腺癌中的预后价值。
Prostate. 1988;13(3):249-56. doi: 10.1002/pros.2990130307.
8
The relation between calcium absorption, serum dehydroepiandrosterone, and vertebral mineral density in postmenopausal women.绝经后女性钙吸收、血清脱氢表雄酮与椎骨矿物质密度之间的关系。
J Clin Endocrinol Metab. 1985 Apr;60(4):651-7. doi: 10.1210/jcem-60-4-651.
9
Orchidectomy versus oestrogen for prostatic cancer: cardiovascular effects.睾丸切除术与雌激素治疗前列腺癌:心血管效应
Br Med J (Clin Res Ed). 1986 Aug 16;293(6544):413-5. doi: 10.1136/bmj.293.6544.413.
10
C19 adrenal steroids enhance prostaglandin F2 alpha output by human endometrium in vitro.
Am J Obstet Gynecol. 1988 Aug;159(2):500-4. doi: 10.1016/s0002-9378(88)80117-0.